紫龙金片辅助化疗治疗老年晚期非小细胞肺癌的效果及对患者免疫功能的影响  

Therapeutic effect of Zilongjin tablets combined with chemotherapy on elderly advanced non-small cell lung cancer and its influence on immune function

作　　者：黄浩飞 蒋征奎 苏永林 胡彦辉 Huang Haofei;Jiang Zhengkui;Su Yonglin;Hu Yanhui(Department of Pharmacy,Zhengzhou University Affiliated Cancer Hospital,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Integrated Traditional Chinese and Western Medicine,Zhengzhou University Affiliated Cancer Hospital,Henan Cancer Hospital,Zhengzhou 450008,China)

机构地区：[1]郑州大学附属肿瘤医院,河南省肿瘤医院药学部,郑州450008 [2]郑州大学附属肿瘤医院,河南省肿瘤医院中西医结合科,郑州450008

出　　处：《中国实用医刊》2024年第23期110-113,共4页Chinese Journal of Practical Medicine

摘　　要：目的研究紫龙金片辅助化疗治疗老年晚期非小细胞肺癌(NSCLC)的效果及对患者免疫功能的影响。方法队列研究。抽取2022年1月至2022年12月郑州大学附属肿瘤医院收治的老年晚期NSCLC患者62例,按随机数字表法分为单一组和联合组,每组31例。单一组采用化疗药物治疗,联合组在化疗药物基础上联合紫龙金片治疗。对比两组疾病控制率、自然杀伤细胞(NK)和白细胞介素-2(IL-2)、免疫功能[T淋巴细胞亚群(CD3^(+)、CD4^(+))]水平、生活质量及不良反应。结果联合组疾病控制率(70.97%,22/31)与单一组(54.84%,17/31)比较差异未见统计学意义(P>0.05)。治疗后,联合组NK细胞、IL-2水平高于单一组(P<0.05),CD3^(+)、CD4^(+)高于单一组(P<0.05),KPS评分高于单一组(P<0.05)。联合组恶心呕吐发生率(22.58%,7/31)、骨髓抑制发生率(12.90%,4/31)、肝肾功能损伤发生率(9.68%,3/31)与单一组(29.03%,9/31;25.81%,8/31;12.90%,4/31)比较差异未见统计学意义(P>0.05)。结论紫龙金片辅助化疗治疗老年晚期NSCLC效果显著,能改善患者免疫功能,提高患者生活质量,且不良反应较少,安全性良好。Objective To study the therapeutic effect of chemotherapy combined with Zilongjin tablets on elderly patients with advanced non-small cell lung cancer(NSCLC),and to investigate the influence on patients’immune function.Methods Sixty-two elderly patients with advanced NSCLC treated in Zhengzhou University Affiliated Cancer Hospital from January 2022 to December 2022 were selected for the cohort study.And they were divided into a single group and a combination group according to the random number table method,with 31 cases in each group.The single group was treated with chemotherapy drugs,and the combination group was treated with Zilongjin tablets on the basis of chemotherapy drugs.Disease control rate,levels of natural killer cells(NK)and interleukin-2(IL-2),immune function assessed T lymphocyte subsets including cluster of differentiation 3^(+)(CD3^(+))and cluster of differentiation 4^(+)(CD4^(+)),quality of life,and incidence of adverse reactions were compared between the two groups.Results There was no significant difference in disease control rate between the combination group(70.97%,22/31)and the single group(54.84%,17/31),P>0.05.After treatment,the levels of NK and IL-2 in the combination group were higher than those in the single group(P<0.05),while CD3^(+)and CD4^(+)in the combination group were higher than those in the single group(P<0.05).The Karnofsky performance status(KPS)score of the combination group was higher than that of single group(P<0.05).The incidence of nausea and vomiting(22.58%,7/31),bone marrow suppression(12.90%,4/31)and liver and kidney dysfunction(9.68%,3/31)of the combination group had no significant difference with the single group(29.03%,9/31;25.81%,8/31;12.90%,4/31),P>0.05.Conclusions Zilongjin tablet assisted chemotherapy in the treatment of elderly advanced NSCLC has significant effect,moreover,it can improve the immune function and quality of life,with fewer adverse reactions and good safety.

关 键 词：非小细胞肺癌 晚期 老年 紫龙金片 化疗 

分 类 号：R73[医药卫生—肿瘤]